| 2026-08-13 | Press release | Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th |
| 2026-08-10 | Press release | Aspire Biopharma Completes Acquisition of Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ |
| 2026-07-20 | Press release | Freestyle Motocross Legend Jarryd McNeil Named Newest Sponsored Athlete for Aspire Biopharma’s BUZZ BOMB(TM) |
| 2026-06-24 | Press release | Aspire Biopharma’s BUZZ BOMB(TM) Launches on Amazon, Introducing Next-Generation Caffeine Stick Packs |
| 2026-06-17 | Press release | Aspire Biopharma to Present at the Life Sciences Investor Forum on June 25th |
| 2026-06-12 | Press release | Aspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems, a Lead |
| 2026-05-28 | Press release | Aspire Biopharma Issues Shareholder Letter |
| 2026-05-27 | Press release | Aspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of Members |
| 2026-05-07 | Press release | Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio |
| 2026-04-27 | Press release | Aspire Biopharma Announces $5.0 Million Share Repurchase Program |
| 2026-04-20 | Press release | Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Sec |
| 2026-04-17 | Press release | Aspire Biopharma’s Buzz Bomb(TM) Caffeine Company’s Brand Ambassador, Ashley Paulson, to Attempt Fastest 100 |
| 2026-04-16 | Press release | Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year Hi |
| 2026-04-15 | Press release | Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion |
| 2026-03-19 | Press release | Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion |
| 2026-03-17 | Press release | Aspire Biopharma’s Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director |
| 2026-03-12 | Press release | Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026 |
| 2026-03-10 | Press release | Aspire Biopharma’s BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack |
| 2026-03-04 | Presentation | I Accept |
| 2026-03-03 | Press release | Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faste |
| 2026-02-25 | Press release | Aspire Biopharma’s Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following Wo |
| 2026-02-20 | Press release | Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements |
| 2026-02-19 | Press release | Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record |
| 2026-02-17 | Press release | Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Gene |
| 2026-02-13 | Press release | Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors |
| 2026-02-12 | Press release | Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Ge |
| 2026-02-11 | Press release | Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Posit |
| 2026-02-10 | Press release | Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement |
| 2026-02-05 | Press release | Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innov |
| 2026-02-03 | Press release | Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Sou |
| 2026-01-29 | Press release | Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin |
| 2026-01-27 | Press release | Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (G |
| 2026-01-22 | Press release | Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Id |
| 2026-01-21 | Press release | Aspire Biopharma’s Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign |
| 2026-01-20 | Press release | Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam – Ge |
| 2026-01-14 | Press release | Aspire Biopharma Announces Reverse Stock Split |
| 2026-01-07 | Press release | Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA) |
| 2025-12-12 | Press release | Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements |
| 2025-12-04 | Press release | Aspire Biopharma Provides Q3 2025 Business Update |
| 2025-12-02 | Press release | Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Tre |